Nasser, Azmi
Hull, Joseph T.
Liranso, Tesfaye
Fry, Nicholas
Cutler, Andrew J.
Rubin, Jonathan
Childress, Ann
Funding for this research was provided by:
Supernus Pharmaceuticals
Article History
Accepted: 6 October 2022
First Online: 4 November 2022
Declarations
:
: This letter was supported by Supernus Pharmaceuticals, Inc.
: AN, JTH, TL, NF, and JR are employees of Supernus Pharmaceuticals, Inc. AJC has received research support from Aevi Genomics, Akili Interactive, Arbor Pharmaceuticals, Ironshore Pharmaceuticals, Janssen, KemPharm, Lundbeck, Neos Therapeutics (now Aytu BioPharma), Neurovance, Noven, Otsuka, Purdue Canada, Rhodes Pharmaceuticals, Shire, Sunovion, Supernus Pharmaceuticals, Inc., Takeda, and Tris Pharma. He has received fees for consulting, advisory boards, and promotional speaking from Adlon Therapeutics, Aevi Genomics, Akili Interactive, Arbor Pharmaceuticals, Atentiv, Cingulate Therapeutics, Corium, Ironshore Pharmaceuticals, Janssen, Lundbeck, MedAvante-ProPhase, Neos Therapeutics (now Aytu BioPharma), NLS Pharmaceutics, Noven, Otsuka, Shire, Sunovion, Supernus Pharmaceuticals, Inc., Takeda, and Tris Pharma. He is an employee and board member of the Neuroscience Education Institute. AC has received research support from, served as a consultant or speaker for, or served on an advisory board for Allergan, Takeda (Shire), Emalex, Pearson, Akili, Arbor, Cingulate Therapeutics, Ironshore, Lumos, Aevi Genomic Medicine, Neos Therapeutics, Neurovance, Noven, Otsuka, Pfizer, Purdue, Adlon, Rhodes, Sunovion, Tris, KemPharm, Supernus Pharmaceuticals, Inc., the U.S. FDA, NLS Pharma, and Jazz.
: Not applicable.
: Not applicable.
: Not applicable.
: The data are not available in a repository, but requests can be directed to <u>anasser@supernus.com.</u>
: Not applicable.
: All authors (AN, JTH, TL, NF, JR, AJC, and AC) participated in the writing and editing process of this submission. All authors have read and approved the final submitted manuscript and agree to be accountable for this work.